NASDAQ:ASNS - Arsanis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.74 -0.19 (-4.83 %) (As of 12/14/2018 04:00 PM ET)Previous Close$3.74Today's Range$3.56 - $4.083452-Week Range$1.15 - $28.69Volume683,614 shsAverage Volume5.13 million shsMarket Capitalization$56.26 millionP/E Ratio-0.23Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Receive ASNS News and Ratings via Email Sign-up to receive the latest news and ratings for ASNS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASNS Previous Symbol CUSIPN/A Webwww.arsanis.com Phone781-819-5704 Debt Debt-to-Equity Ratio0.28 Current Ratio5.08 Quick Ratio5.08 Price-To-Earnings Trailing P/E Ratio-0.23 Forward P/E Ratio-1.26 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.87 Profitability EPS (Most Recent Fiscal Year)($16.23) Net Income$-33,870,000.00 Net MarginsN/A Return on Equity-103.84% Return on Assets-70.75% Miscellaneous Employees43 Outstanding Shares14,310,000Market Cap$56.26 million OptionableNot Optionable Arsanis (NASDAQ:ASNS) Frequently Asked Questions What is Arsanis' stock symbol? Arsanis trades on the NASDAQ under the ticker symbol "ASNS." How were Arsanis' earnings last quarter? Arsanis Inc (NASDAQ:ASNS) announced its quarterly earnings data on Friday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.02. View Arsanis' Earnings History. When is Arsanis' next earnings date? Arsanis is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for Arsanis. What price target have analysts set for ASNS? 4 brokerages have issued 12 month price targets for Arsanis' shares. Their predictions range from $2.50 to $26.00. On average, they anticipate Arsanis' share price to reach $14.25 in the next twelve months. This suggests a possible upside of 281.0% from the stock's current price. View Analyst Price Targets for Arsanis. What is the consensus analysts' recommendation for Arsanis? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arsanis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arsanis. What are Wall Street analysts saying about Arsanis stock? Here are some recent quotes from research analysts about Arsanis stock: 1. According to Zacks Investment Research, "Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company's product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. " (11/14/2018) 2. Cantor Fitzgerald analysts commented, "As the company advances its pipeline toward commercialization, we expect catalysts to drive Arsanis’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target." (6/28/2018) Has Arsanis been receiving favorable news coverage? Media stories about ASNS stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arsanis earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Are investors shorting Arsanis? Arsanis saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,173,598 shares, an increase of 106.8% from the November 15th total of 567,470 shares. Based on an average daily trading volume, of 8,343,897 shares, the days-to-cover ratio is currently 0.1 days. View Arsanis' Current Options Chain. Who are some of Arsanis' key competitors? Some companies that are related to Arsanis include ADMA Biologics (ADMA), Eiger Biopharmaceuticals (EIGR), LogicBio Therapeutics (LOGC), Idera Pharmaceuticals (IDRA), Allena Pharmaceuticals (ALNA), Compugen (CGEN), Neon Therapeutics (NTGN), Erytech Pharma (ERYP), Jounce Therapeutics (JNCE), Organovo (ONVO), Fennec Pharmaceuticals (FENC), Nantkwest (NK), Champions Oncology (CSBR), Pluristem Therapeutics (PSTI) and Aptose Biosciences (APTO). Who are Arsanis' key executives? Arsanis' management team includes the folowing people: Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 54)Mr. Michael P. Gray CPA, M.B.A., MBA, CPA, Pres, CEO & CFO (Age 47)Dr. Anthony Christopher Stevens, Chief Medical Officer (Age 59)Dr. Eszter Nagy, Co-Founder (Age 52)Mr. David S. Mantus, Chief Devel. Officer (Age 55) When did Arsanis IPO? (ASNS) raised $50 million in an initial public offering (IPO) on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO. Who are Arsanis' major shareholders? Arsanis' stock is owned by many different of retail and institutional investors. Top institutional investors include Alambic Investment Management L.P. (0.93%). Company insiders that own Arsanis stock include Polaris Venture Management Co and Tillman U Gerngross. View Institutional Ownership Trends for Arsanis. Which major investors are buying Arsanis stock? ASNS stock was bought by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P.. Company insiders that have bought Arsanis stock in the last two years include Polaris Venture Management Co and Tillman U Gerngross. View Insider Buying and Selling for Arsanis. How do I buy shares of Arsanis? Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arsanis' stock price today? One share of ASNS stock can currently be purchased for approximately $3.74. How big of a company is Arsanis? Arsanis has a market capitalization of $56.26 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 43 workers across the globe. What is Arsanis' official website? The official website for Arsanis is http://www.arsanis.com. How can I contact Arsanis? Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected] MarketBeat Community Rating for Arsanis (NASDAQ ASNS)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 141 (Vote Outperform)Underperform Votes: 178 (Vote Underperform)Total Votes: 319MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: Day Trading - Risk Worth the Reward?